Methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA.
1. A method of treating mucopolysaccharidosis IIIB (MPS IIIB) in a patient in need thereof comprising:
(i) intravenously administering to the patient about 1×10 13 to about 1×10 16 vg/kg of a recombinant adeno-associated virus 9 (rAAV9) comprising a single-stranded genome expressing an α-N-acetylglucosaminidase (NAGLU) polynucleotide, wherein the rAAV9-NAGLU genome consists essentially of the polynucleotide sequence of SEQ ID NO: 5; and
(ii) expressing the encoded NAGLU polypeptide in neurons, glia cells, and endothelial cells of the central nervous system of the patient;
wherein the administration and expression are effective to:
(a) alleviate lysosomal storage lesions in the central nervous system, peripheral nervous system and other somatic tissues,
(b) alleviate neuropathology, astrocytosis and/or neurodegeneration in the central nervous system and peripheral nervous system, and
(c) restore α-N-acetylglucosaminidase (NAGLU) activity in somatic tissues;
wherein mannitol is not administered to the patient prior to administering the rAAV9.
2. The method of claim 1 , further comprising testing the patient for neuroinflammation after the rAAV9 has been administered.
3. The method of claim 1 , further comprising testing for systemic expression of the polynucleotide in the peripheral central nervous system of the patient.
4. The method of claim 1 , comprising administering about 1×10 13 vg/kg of the rAAV9.
5. The method of claim 1 , comprising administering about 1×10 14 vg/kg of the rAAV9.
6. The method of claim 1 , comprising administering about 1×10 15 vg/kg of the rAAV9.
7. The method of claim 1 , comprising administering about 1×10 16 vg/kg of the rAAV9.